Noida, India (PressExposure) June 28, 2011 -- Obesity has emerged as a new epidemic in the country due to which the number of deaths has been increasing in the country. Studies conducted by WHO has concluded that, prevalence of overweight in men aged 30 years and above will rise from 22% in 2005 to 31% in 2015. On the contrary, prevalence among females aged 30 years and above will rise from 21% in 2005 to 29% in 2015. As a result of such high occurrence of this disease in the country, the obesity drug market in India is estimated to surpass INR 25 Billion in 2011, says our new research report "Global Obesity Drug Market Analysis". Although the prevalence is quite less compared to other developed and developing economies, owned by large population base, India provides a huge customer base to the player's active in the market.
Additionally, India is witnessing an increasing number of patients coming from the US and Middle-East to undergo surgical procedures for morbid obesity. This has also surged the anti obesity market in the country. Moreover, on account of increasing awareness among the people and rising per capita income of the people, the market is expected to render higher revenue in the coming years.
Our report has provided extensive information of the major drugs prevalent in the market, such as Orlistat/Xenical, Meridia, Acomplia, and Alli. Besides, detail description of the obesity drugs that are in pipeline are estimated to be launched in near future. Most importantly, we have segmented the global market into regions, such as North America, Latin America, Europe, Asia-Pacific, and the MEA region. Various countries of these regions along with the situation of obesity epidemic in these countries have been included in our report.
"Global Obesity Drug Market Analysis" also provides information of the key competitors in the market along with their business information and areas of expertise. The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past and future performance of the industry. The report provides an extensive research on the recent trends of the global obesity drug market along with the impartial analysis considering the impact of financial crisis on its performance.
For FREE SAMPLE of this report visit: [http://www.rncos.com/Report/IM335.htm]
Check DISCOUNTED REPORTS on: http://www.rncos.com/promotion.htm